Inclusion Criteria:

- Histologically or cytologically documented inoperable, locally advanced, metastatic
or recurrent NSCLC other than squamous cell

- At least 1 measurable lesion according to RECIST criteria

- ECOG performance score 0 or 1

- Age between 18 and 70 years

Exclusion Criteria:

- Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a
predominant squamous component.

- History of haemoptysis

- Evidence of tumour invading major blood vessels on imaging.

- Previous neoadjuvant/adjuvant chemotherapy.

- Previous radiotherapy.

- Serious uncontrolled coagulation disorder or thrombo-embolic complications within 6
months prior to study start or history of serious bleeding complications.

- Major surgical procedures within 4 weeks prior to study entry.

- Minor surgery, including insertion of an indwelling catheter, within 24 hours prior
to the first bevacizumab infusion.

- Non-healing wound, active peptic ulcer or bone fracture.

- History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
within 6 months of enrolment.